Pharma Equity Group A/S Cl A Asset Resilience Ratio
Pharma Equity Group A/S Cl A asset resilience ratio. Pharma Equity Group A/S Cl A (PEG) has an Asset Resilience Ratio of 2.24% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Pharma Equity Group A/S Cl A (PEG) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pharma Equity Group A/S Cl A (2008–2018)
Asset resilience ratio of Pharma Equity Group A/S Cl A from 2008 to 2018. This chart shows how Pharma Equity Group A/S Cl A's Asset Resilience Ratio has changed over time. Read debt load of Pharma Equity Group A/S Cl A for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pharma Equity Group A/S Cl A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Pharma Equity Group A/S Cl A assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr1.72 Million | 2.24% |
| Total Liquid Assets | Dkr1.72 Million | 2.24% |
Asset Resilience Insights
- Limited Liquidity: Pharma Equity Group A/S Cl A maintains only 2.24% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pharma Equity Group A/S Cl A Industry Peers by Asset Resilience Ratio
Compare Pharma Equity Group A/S Cl A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Pharma Equity Group A/S Cl A Asset Resilience Ratio by Year (2008–2018)
Pharma Equity Group A/S Cl A asset resilience ratio by year from 2008 to 2018. The table below shows the annual Asset Resilience Ratio data for Pharma Equity Group A/S Cl A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-09-30 | 2.13% | Dkr1.72 Million ≈ $269.58K |
Dkr80.84 Million ≈ $12.65 Million |
+1.06pp |
| 2016-09-30 | 1.07% | Dkr1.35 Million ≈ $210.90K |
Dkr125.75 Million ≈ $19.67 Million |
-0.27pp |
| 2015-09-30 | 1.34% | Dkr1.69 Million ≈ $264.10K |
Dkr126.25 Million ≈ $19.75 Million |
-5.61pp |
| 2012-09-30 | 6.95% | Dkr35.00 Million ≈ $5.48 Million |
Dkr503.85 Million ≈ $78.83 Million |
+0.05pp |
| 2011-09-30 | 6.89% | Dkr35.00 Million ≈ $5.48 Million |
Dkr507.76 Million ≈ $79.44 Million |
-69.48pp |
| 2008-09-30 | 76.37% | Dkr199.84 Million ≈ $31.27 Million |
Dkr261.67 Million ≈ $40.94 Million |
-- |
About Pharma Equity Group A/S Cl A
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which the current therapy is lacking or in need of improvement. Its products under development, includes RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment… Read more